In his position, Elam will drive customer satisfaction and continue to expand Capitol’s involvement in local, national and international markets. Before joining Capitol Scientific, Elam worked as a
In his position, Elam will drive customer satisfaction and continue to expand Capitol’s involvement in local, national and international markets. Before joining Capitol Scientific, Elam worked as a
The company has posted a net loss of $19.3m for the year ended 30 June 2010, or $0.83 loss per diluted share, compared to net loss of $22.37m,
The company said that if its AM152 IND got accepted by the FDA, it will be eligible to commence Phase 1 safety studies with the compound in healthy
RBC said that this appointment is the result of the step down of Mike Zaleski as RBC’s president and CEO effective 22 October 2010. Prior to joining RBC,
Sort Out IV, a randomised trial, was designed to test whether the Xience V stent is non-inferior to the Cypher stent. Reportedly, both drug-eluting stents performed better than
As per the terms of the contract, ATS will continue to provide software development services for the NCI Center for Biomedical Informatics and Information Technology (CBIIT) in support
Discovered by Otsuka Pharma, OPA-6566 is currently under development by Otsuka Pharma for the treatment of glaucoma, in the US. As per the agreement, Otsuka Pharma will allow
Pfizer said that the discontinuation resulted from a scheduled interim analysis by an independent Data Monitoring Committee (DMC) which found that the combination of sunitinib with prednisone was
Centocor has submitted the sBLA seeking to expand the Simponi (golimumab) physician label to include inhibiting the progression of structural damage, inducing major clinical response (MCR) and maintenance
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.